Search results for "major depressive disorder"

showing 10 items of 122 documents

Shared genetic risk between eating disorder- and substance-use-related phenotypes: Evidence from genome-wide association studies

2020

AbstractEating disorders and substance use disorders frequently co-occur. Twin studies reveal shared genetic variance between liabilities to eating disorders and substance use, with the strongest associations between symptoms of bulimia nervosa (BN) and problem alcohol use (genetic correlation [rg], twin-based=0.23-0.53). We estimated the genetic correlation between eating disorder and substance use and disorder phenotypes using data from genome-wide association studies (GWAS). Four eating disorder phenotypes (anorexia nervosa [AN], AN with binge-eating, AN without binge-eating, and a BN factor score), and eight substance-use-related phenotypes (drinks per week, alcohol use disorder [AUD], …

Netherlands Twin Register (NTR)Alcoholism/geneticsSchizophrenia/genetics[SDV]Life Sciences [q-bio][SDV.MHEP.PSM] Life Sciences [q-bio]/Human health and pathology/Psychiatrics and mental healthMedizinMedicine (miscellaneous)Genome-wide association studyAlcohol use disorderAnorexia nervosaLinkage Disequilibriumddc:616.89[SCCO]Cognitive science0302 clinical medicineRisk FactorsTobacco Use Disorder/geneticsSubstance-Related Disorders/genetics0303 health sciences[SDV.MHEP] Life Sciences [q-bio]/Human health and pathologyFactors de risc en les malaltiesBulimia nervosaFeeding and Eating Disorders/geneticseating disorders; genetic correlation; substance useTobacco Use Disordergenetic correlation3. Good healthFenotip[SDV] Life Sciences [q-bio]Psychiatry and Mental healthAlcoholismEating disordersPhenotypeSchizophreniaDrinking of alcoholic beverageseating disorderConsum d'alcoholMajor depressive disorder/dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_beingmedicine.symptomDepressive Disorder Major/geneticseating disorders genetic correlation substance useClinical psychologySubstance abuseRisk factors in diseasesSubstance-Related Disorderssubstance useeating disordersPolymorphism Single NucleotideArticleFeeding and Eating Disorders03 medical and health sciencesSDG 3 - Good Health and Well-beingmental disorders/dk/atira/pure/keywords/cohort_studies/netherlands_twin_register_ntr_GeneticsmedicineHumansTrastorns de la conducta alimentària030304 developmental biologyGenetic associationPharmacologyeating disorders ; genetic correlation ; substance useDepressive Disorder MajorBinge eatingbusiness.industry[SCCO.NEUR]Cognitive science/Neuroscience[SCCO.NEUR] Cognitive science/Neurosciencesubstance use.[SCCO] Cognitive sciencemedicine.diseaseComorbidityTwin study030227 psychiatryAbús de substàncies[SDV.MHEP.PSM]Life Sciences [q-bio]/Human health and pathology/Psychiatrics and mental healthSchizophreniabusinessGenètica030217 neurology & neurosurgery[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyGenome-Wide Association Study
researchProduct

Genetic relationship between five psychiatric disorders estimated from genome-wide SNPs

2013

AM Vicente - Cross-Disorder Group of the Psychiatric Genomics Consortium Most psychiatric disorders are moderately to highly heritable. The degree to which genetic variation is unique to individual disorders or shared across disorders is unclear. To examine shared genetic etiology, we use genome-wide genotype data from the Psychiatric Genomics Consortium (PGC) for cases and controls in schizophrenia, bipolar disorder, major depressive disorder, autism spectrum disorders (ASD) and attention-deficit/hyperactivity disorder (ADHD). We apply univariate and bivariate methods for the estimation of genetic variation within and covariation between disorders. SNPs explained 17-29% of the variance in …

Netherlands Twin Register (NTR)MedizinInheritance PatternsSocial SciencesAUTISM SPECTRUM DISORDERSnosologyheritabilityCOMMON SNPS0302 clinical medicineCrohn DiseaseSCHIZOPHRENIAChildPsychiatric geneticsGenetics & HeredityMAJOR DEPRESSIVE DISORDERRISK0303 health sciencesATTENTION-DEFICIT/HYPERACTIVITY DISORDER120 000 Neuronal CoherenceMental DisordersVariantsBIPOLAR DISORDERASSOCIATIONGenomic disorders and inherited multi-system disorders [DCN PAC - Perception action and control IGMD 3]Psychiatric DisordersCROHNS-DISEASE3. Good healthSchizophreniagenetic association studyMedical geneticsMajor depressive disorderSNPsAdultmedicine.medical_specialtygenetic etiologymedical geneticsDEFICIT HYPERACTIVITY DISORDERBiologyPolymorphism Single Nucleotidebehavioral disciplines and activitiesArticleGenomic disorders and inherited multi-system disorders DCN MP - Plasticity and memory [IGMD 3]HeritabilityGenetic Heterogeneity03 medical and health sciencesPrevalence of mental disordersmental disorders/dk/atira/pure/keywords/cohort_studies/netherlands_twin_register_ntr_[SDV.BBM] Life Sciences [q-bio]/Biochemistry Molecular BiologyGeneticsmedicineddc:61HumansAttention deficit hyperactivity disorderGenetic Predisposition to Disease[SDV.BBM]Life Sciences [q-bio]/Biochemistry Molecular BiologyDCN PAC - Perception action and control NCEBP 9 - Mental healthddc:610Medizinische Fakultät » Universitätsklinikum Essen » LVR-Klinikum Essen » Klinik für Psychiatrie Psychosomatik und Psychotherapie des Kindes- und JugendaltersBipolar disorderPsychiatry030304 developmental biologyDepressive Disorder MajorGenome HumanGenetic heterogeneitymedicine.diseaseschizophreniaAttention Deficit Disorder with HyperactivityChild Development Disorders PervasivePerturbações do Desenvolvimento Infantil e Saúde Mental030217 neurology & neurosurgeryGenome-Wide Association Study
researchProduct

Lamotrigine compared to placebo and other agents with antidepressant activity in patients with unipolar and bipolar depression: a comprehensive meta-…

2016

ObjectivesTo meta-analytically summarize lamotrigine’s effectiveness and safety in unipolar and bipolar depression.MethodsWe conducted systematic PubMed and SCOPUS reviews (last search =10/01/2015) of randomized controlled trials comparing lamotrigine to placebo or other agents with antidepressant activity in unipolar or bipolar depression. We performed a random-effects meta-analysis of depression ratings, response, remission, and adverse effects calculating standardized mean difference (SMD) and risk ratio (RR) ±95% confidence intervals (CIs).ResultsEighteen studies (n=2152, duration=9.83 weeks) in patients with unipolar depression (studies=4, n=187; monotherapy vs lithium=1, augmentation …

Olanzapinemedicine.medical_specialtyBipolar DisorderLithium (medication)Bipolar depressionBipolar depression bipolar disorder lamotrigine major depressive disorder trials unipolar depressionCitalopramLithiumCitalopramLamotrigineLamotriginePlaceboBipolar depression; bipolar disorder; lamotrigine; major depressive disorder; trials; unipolar depressionBenzodiazepines03 medical and health sciences0302 clinical medicineAntimanic AgentsFluoxetineInternal medicinemedicineHumansBipolar disorderunipolar depressionPsychiatryDepressive Disorder MajorFluoxetinemajor depressive disorderDepressionTriazinesbusiness.industrytrialsmedicine.diseaseAntidepressive Agents030227 psychiatryDrug CombinationsPsychiatry and Mental healthVitamin B ComplexMajor depressive disorderAnticonvulsantsNeurology (clinical)businessInositol030217 neurology & neurosurgeryAntipsychotic Agentsmedicine.drug
researchProduct

Early reactions of brain-derived neurotrophic factor in plasma (pBDNF) and outcome to acute antidepressant treatment in patients with Major Depressio…

2011

Abstract In Major Depressive Disorder, a growing data base suggests that the onset of antidepressants’ action can be detected by improvement of depressive symptoms in the first 10–14 days of treatment. Previous studies showed that the mean concentration of the brain-derived neurotrophic factor (BDNF) in blood increases during antidepressant treatment and positively correlates with amelioration of MDD symptoms. We previously showed an association between very early changes of the serum BDNF concentration and treatment outcome ( Tadic et al., 2011 . Prog Neuropsychopharmacol Biol Psychiatry 35, 415–420). However, no study has yet investigated whether BDNF concentration in plasma increases in …

OncologyAdultMalemedicine.medical_specialtyTime FactorsEnzyme-Linked Immunosorbent AssayCellular and Molecular NeuroscienceYoung AdultNeurotrophic factorsInternal medicineHamdmedicineHumansPsychiatryDepression (differential diagnoses)PharmacologyBrain-derived neurotrophic factorPsychiatric Status Rating ScalesDepressive Disorder MajorInpatientsBrain-Derived Neurotrophic FactorMiddle Agedmedicine.diseaseAntidepressive AgentsROC CurveLinear ModelsAntidepressantBiomarker (medicine)Major depressive disorderAnxietyFemalemedicine.symptomPsychologyNeuropharmacology
researchProduct

2020

Withdrawal symptoms after discontinuation of antidepressants are common and have long been known. Typical symptoms after dose reduction or discontinuation of antidepressants are dizziness, drowsiness, headache, flu-like symptoms, hyperarousal, imbalance, insomnia, irritability, and nausea. Rebound, relapse, or recurrence associated with the underlying mental disorder may also occur. The occurrence of obsessive-compulsive symptoms (OCS) following abrupt discontinuation of antidepressants have not yet been reported. Here we report the development of OCS (obsessional suicidal thoughts) in a patient with major depressive disorder and absence of a previous obsessive-compulsive disorder following…

Pediatricsmedicine.medical_specialtyNauseabusiness.industryVenlafaxinemedicine.diseaseIrritabilityObsessive compulsive symptoms030227 psychiatryDiscontinuation03 medical and health sciencesPsychiatry and Mental health0302 clinical medicinemedicineEscitalopramMajor depressive disordermedicine.symptombusiness030217 neurology & neurosurgeryDepression (differential diagnoses)medicine.drugFrontiers in Psychiatry
researchProduct

Are Polygenic Risk Scores for Major Mental Disorders Associated with General or Specific Psychosis Symptom dimensions?

2019

Background Psychotic symptoms can be conceptualised as dimensions of psychopathology cutting across diagnostic boundaries. Thus, they might be considered enhanced quantitative phenotypes to relate to genetic variants as summarised by Polygenic Risk Scores (PRSs) for Major Mental Disorders (MMDs), including Schizophrenia (SZ), Bipolar Disorder (BP), and Major Depressive Disorder (MDD). The objectives of this study were to: 1) identify the dimensional structure of symptoms at First Episode Psychosis (FEP), testing whether a bi-factor model statistically fits the conceptualization of psychosis as a single common construct (general psychosis factor) while also recognising multidimensionality (p…

PharmacologyPsychosisOdds ratiomedicine.diseasePopulation stratificationschizophrenia poligenic risk scorePsychiatry and Mental healthNeurologySchizophreniamedicineMajor depressive disorderPharmacology (medical)Neurology (clinical)Bipolar disordermedicine.symptomPsychologyManiaSettore MED/25 - PsichiatriaBiological PsychiatryPsychopathologyClinical psychology
researchProduct

Response und Remission in der Psychotherapieforschung

2010

Treatment effects of psychotherapy are usually studied using analysis of mean differences, tests of significance and effect size measures. These strategies, however, do not answer the question of how large the proportion of patients is who responded to treatment or who even reached remission. This article compares 2 competing methods of response and remission analysis: The Reliable Change Index (RCI) according to Jacobson et al. and the method of percent symptom reduction (PSR). We applied both methods using a sample of 338 patients with DSM-IV major depressive disorder. A pre-post treatment effect of Cohen's d=1,16 (intention-to-treat) resulted for the Beck Depression Inventory (BDI), corr…

Psychiatry and Mental healthClinical PsychologyPsychotherapistTreatment outcomeBeck Depression InventorymedicineMajor depressive disorderTreatment effectSymptom reductionmedicine.diseasePsychologyApplied PsychologyDepression (differential diagnoses)PPmP - Psychotherapie · Psychosomatik · Medizinische Psychologie
researchProduct

Acceptance and Commitment Therapy for Major Depressive Disorder: Insights into a New Generation of Face-to-Face Treatment and Digital Self-Help Appro…

2021

Major depressive disorder (MDD) represents a key contributor to the global burden of mental illness given its relatively high lifetime prevalence, frequent comorbidity, and disability rates. Evidence-based treatment options for depression include pharmacotherapy and psychotherapy, such as cognitive behavioral therapy (CBT). Beyond traditional CBT, over 15 years ago, Hayes proclaimed a new generation of contextualistic and process-orientated so-called third wave of CBT interventions, including acceptance and commitment therapy (ACT). Using mindfulness and acceptance as well as commitment and behavior change processes, the transdiagnostic ACT approach aims to increase psychological flexibilit…

PsychotherapistMindfulnessmedicine.medical_treatmentBehavior changeFlexibility (personality)Behavioral activationMental illnessmedicine.diseaseAcceptance and commitment therapyCognitive behavioral therapy03 medical and health sciences0302 clinical medicinemedicineMajor depressive disorder030212 general & internal medicinePsychology
researchProduct

La opinión negativa del sí-mismo en los trastornos depresivos

2002

According to cognitive theory of depression (Beck, 1967, 1976), negatively biased information processing is responsible for maintenance, severity and duration of depressive affect. However, the evidence does not consistently support this assumption. The present study was designed to ascertain if depressed patients have access not only to negative information about the self, but also to positive one. Twenty patients with major depressive disorder, 18 with distimic disorder, and 20 nonpsychiatric controls completed a self-referent task. Instructions to perform the task were manipulated in order to fulfill it taking into account three different time-periods: present, past, and future. Data sho…

SelfNegative informationInformation processingCognitionmedicine.diseaseAffect (psychology)PsicologíaDevelopmental psychologyClinical PracticePsychiatry and Mental healthClinical PsychologymedicineMajor depressive disorderPsychologyDepression (differential diagnoses)Clinical psychologyRevista de Psicopatología y Psicología Clínica
researchProduct

Telomeres in the Brain Cortex of Patients with Major Depressive Disorder

2014

Telomeres are complex structures formed by the end of the DNA molecule at the tip of each chromosomal arm. The repeated (TTAGGG) telomeric sequence progressively shortens during lifespan because it cannot be replicated as somatic cells divide, and is highly susceptible to breakage by free radicals. Critically shortened telomeres activate the genetic program of cell senescence and/or apoptosis. The telomere length measured in peripheral blood leucocytes is considered a reliable marker of biological age, mortality risk and exposure to various pathological conditions, including cardiovascular disease, dementia, and metabolic syndrome. Telomere erosion has been observed in psychiatric disorders…

Senescencemedicine.medical_specialtybusiness.industryCognitive NeuroscienceDiseaseBioinformaticsmedicine.diseaseTelomereBehavioral NeurosciencePsychiatry and Mental healthNeurologyMood disordersSchizophreniamedicineMajor depressive disorderNeurology (clinical)businessPsychiatryPathologicalBiological PsychiatryDepression (differential diagnoses)Activitas Nervosa Superior
researchProduct